AU2013361255B2 - Histone demethylase inhibitors - Google Patents
Histone demethylase inhibitors Download PDFInfo
- Publication number
- AU2013361255B2 AU2013361255B2 AU2013361255A AU2013361255A AU2013361255B2 AU 2013361255 B2 AU2013361255 B2 AU 2013361255B2 AU 2013361255 A AU2013361255 A AU 2013361255A AU 2013361255 A AU2013361255 A AU 2013361255A AU 2013361255 B2 AU2013361255 B2 AU 2013361255B2
- Authority
- AU
- Australia
- Prior art keywords
- preparation
- compound
- mhz
- fluoro
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010074870 Histone Demethylases Proteins 0.000 title abstract description 12
- 102000008157 Histone Demethylases Human genes 0.000 title abstract description 12
- 239000003112 inhibitor Substances 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 415
- 238000000034 method Methods 0.000 claims abstract description 195
- -1 3-aminopyridine derivative compounds Chemical class 0.000 claims abstract description 159
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 239000008194 pharmaceutical composition Chemical class 0.000 claims abstract description 9
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 8
- 206010005003 Bladder cancer Diseases 0.000 claims abstract description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract description 6
- 201000005202 lung cancer Diseases 0.000 claims abstract description 6
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims abstract description 6
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 125
- 150000003839 salts Chemical class 0.000 claims description 93
- 125000001072 heteroaryl group Chemical group 0.000 claims description 84
- 125000000623 heterocyclic group Chemical group 0.000 claims description 77
- 125000003118 aryl group Chemical group 0.000 claims description 71
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 70
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 68
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 68
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 claims description 65
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 65
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims description 64
- 125000003342 alkenyl group Chemical group 0.000 claims description 43
- 125000000304 alkynyl group Chemical group 0.000 claims description 43
- 125000003545 alkoxy group Chemical group 0.000 claims description 38
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 25
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 125000004104 aryloxy group Chemical group 0.000 claims description 20
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 15
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 14
- JAMULYFATHSZJM-UHFFFAOYSA-N 8-(4-dibenzothiophenyl)-2-(4-morpholinyl)-1-benzopyran-4-one Chemical compound O1C2=C(C=3C=4SC5=CC=CC=C5C=4C=CC=3)C=CC=C2C(=O)C=C1N1CCOCC1 JAMULYFATHSZJM-UHFFFAOYSA-N 0.000 claims description 13
- 125000002431 aminoalkoxy group Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 201000011510 cancer Diseases 0.000 abstract description 13
- 238000011282 treatment Methods 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 11
- 230000005764 inhibitory process Effects 0.000 abstract description 10
- 201000001441 melanoma Diseases 0.000 abstract description 4
- 230000001613 neoplastic effect Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 description 351
- 238000005160 1H NMR spectroscopy Methods 0.000 description 127
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- 238000005481 NMR spectroscopy Methods 0.000 description 78
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 description 72
- XLQIGLBALJNHKR-UHFFFAOYSA-N methyl 3-aminopyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1N XLQIGLBALJNHKR-UHFFFAOYSA-N 0.000 description 59
- 101150041968 CDC13 gene Proteins 0.000 description 55
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 55
- 125000002947 alkylene group Chemical group 0.000 description 53
- 238000006243 chemical reaction Methods 0.000 description 50
- 238000000746 purification Methods 0.000 description 46
- 239000007787 solid Substances 0.000 description 43
- 230000007062 hydrolysis Effects 0.000 description 40
- 238000006460 hydrolysis reaction Methods 0.000 description 40
- CZUPBTJBMHZBTJ-UHFFFAOYSA-N 5-fluoro-3-iodo-2h-indazole Chemical compound FC1=CC=C2NN=C(I)C2=C1 CZUPBTJBMHZBTJ-UHFFFAOYSA-N 0.000 description 38
- 239000000243 solution Substances 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 35
- 238000002953 preparative HPLC Methods 0.000 description 35
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 32
- 125000004432 carbon atom Chemical group C* 0.000 description 32
- 150000003254 radicals Chemical class 0.000 description 28
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 26
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 108010033040 Histones Proteins 0.000 description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- 239000000126 substance Substances 0.000 description 22
- 239000000047 product Substances 0.000 description 20
- 238000010898 silica gel chromatography Methods 0.000 description 19
- 150000001204 N-oxides Chemical class 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 235000019439 ethyl acetate Nutrition 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 15
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 14
- 239000002253 acid Substances 0.000 description 14
- 102000006947 Histones Human genes 0.000 description 13
- 101001088893 Homo sapiens Lysine-specific demethylase 4C Proteins 0.000 description 13
- 102100033230 Lysine-specific demethylase 4C Human genes 0.000 description 13
- 125000003709 fluoroalkyl group Chemical group 0.000 description 13
- 239000000651 prodrug Substances 0.000 description 13
- 229940002612 prodrug Drugs 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 12
- 125000004450 alkenylene group Chemical group 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 102100033247 Lysine-specific demethylase 5B Human genes 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 238000007069 methylation reaction Methods 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 10
- 101001088883 Homo sapiens Lysine-specific demethylase 5B Proteins 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
- 235000018977 lysine Nutrition 0.000 description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 101100477411 Dictyostelium discoideum set1 gene Proteins 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000010511 deprotection reaction Methods 0.000 description 8
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 8
- FASOJOLGUAUEPU-UHFFFAOYSA-N methyl 3-bromopyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1Br FASOJOLGUAUEPU-UHFFFAOYSA-N 0.000 description 8
- 230000011987 methylation Effects 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 7
- ZPFBQBOZEDHSGM-UHFFFAOYSA-N 5-chloro-3-iodo-2h-indazole Chemical compound C1=C(Cl)C=CC2=NNC(I)=C21 ZPFBQBOZEDHSGM-UHFFFAOYSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 101000613625 Homo sapiens Lysine-specific demethylase 4A Proteins 0.000 description 7
- 102100040863 Lysine-specific demethylase 4A Human genes 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 235000011181 potassium carbonates Nutrition 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 229910052727 yttrium Inorganic materials 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 6
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 125000003107 substituted aryl group Chemical group 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- IZIWHSYVQDJETA-UHFFFAOYSA-N 3-iodo-5-methyl-2h-indazole Chemical compound CC1=CC=C2NN=C(I)C2=C1 IZIWHSYVQDJETA-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 150000003927 aminopyridines Chemical class 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- XDPCNPCKDGQBAN-UHFFFAOYSA-N 3-hydroxytetrahydrofuran Chemical compound OC1CCOC1 XDPCNPCKDGQBAN-UHFFFAOYSA-N 0.000 description 4
- UDKYMMQGPNFWDA-UHFFFAOYSA-N 3-iodo-2h-indazole Chemical compound C1=CC=CC2=C(I)NN=C21 UDKYMMQGPNFWDA-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 108010077544 Chromatin Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 101001088892 Homo sapiens Lysine-specific demethylase 5A Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 210000003483 chromatin Anatomy 0.000 description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 4
- 230000017858 demethylation Effects 0.000 description 4
- 238000010520 demethylation reaction Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000000464 thioxo group Chemical group S=* 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- RBGNHCYGFBRIRO-UHFFFAOYSA-N 3-[(1-methylpyrrolo[2,3-b]pyridin-3-yl)amino]pyridine-4-carboxylic acid Chemical compound C12=CC=CN=C2N(C)C=C1NC1=CN=CC=C1C(O)=O RBGNHCYGFBRIRO-UHFFFAOYSA-N 0.000 description 3
- FKTYYYISJZEMOF-UHFFFAOYSA-N 5-fluoro-3-nitro-1h-indole Chemical compound C1=C(F)C=C2C([N+](=O)[O-])=CNC2=C1 FKTYYYISJZEMOF-UHFFFAOYSA-N 0.000 description 3
- ZNSMNVMLTJELDZ-UHFFFAOYSA-N Bis(2-chloroethyl)ether Chemical compound ClCCOCCCl ZNSMNVMLTJELDZ-UHFFFAOYSA-N 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 102100033246 Lysine-specific demethylase 5A Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 150000005840 aryl radicals Chemical class 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 150000001733 carboxylic acid esters Chemical class 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- IMBKASBLAKCLEM-UHFFFAOYSA-L ferrous ammonium sulfate (anhydrous) Chemical compound [NH4+].[NH4+].[Fe+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O IMBKASBLAKCLEM-UHFFFAOYSA-L 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 3
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 3
- 239000011755 sodium-L-ascorbate Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- FSNGFFWICFYWQC-UHFFFAOYSA-N 1-(2-chloroethyl)pyrrolidine;hydron;chloride Chemical compound Cl.ClCCN1CCCC1 FSNGFFWICFYWQC-UHFFFAOYSA-N 0.000 description 2
- JWUDRDSLEKRMMY-UHFFFAOYSA-N 1-(2-cyclopropylethyl)-5-fluoro-3-iodoindazole Chemical compound N1=C(I)C2=CC(F)=CC=C2N1CCC1CC1 JWUDRDSLEKRMMY-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- RJTCGQSGWPAMME-UHFFFAOYSA-N 2-(2-cyclopropylethyl)-5-fluoro-3-iodoindazole Chemical compound IC1=C2C=C(F)C=CC2=NN1CCC1CC1 RJTCGQSGWPAMME-UHFFFAOYSA-N 0.000 description 2
- KCGOMSMXZAEGCO-UHFFFAOYSA-N 2-(5-bromopentyl)-5-fluoro-3-iodoindazole Chemical compound C1=C(F)C=CC2=NN(CCCCCBr)C(I)=C21 KCGOMSMXZAEGCO-UHFFFAOYSA-N 0.000 description 2
- YSYWPDPSEKXLRJ-UHFFFAOYSA-N 2-(cyclobutylmethyl)-5-fluoro-3-iodoindazole Chemical compound IC1=C2C=C(F)C=CC2=NN1CC1CCC1 YSYWPDPSEKXLRJ-UHFFFAOYSA-N 0.000 description 2
- ZWPQXZJJRHWUNM-UHFFFAOYSA-N 2-(cyclopentylmethyl)-5-fluoro-3-iodoindazole Chemical compound IC1=C2C=C(F)C=CC2=NN1CC1CCCC1 ZWPQXZJJRHWUNM-UHFFFAOYSA-N 0.000 description 2
- AQOBXPYWTZUHPR-UHFFFAOYSA-N 2-(cyclopropylmethyl)-5-fluoro-3-iodoindazole Chemical compound IC1=C2C=C(F)C=CC2=NN1CC1CC1 AQOBXPYWTZUHPR-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OACWLLVFJAJSBC-UHFFFAOYSA-N 2-[2-(2-chloroethoxy)ethyl]-5-fluoro-3-iodoindazole Chemical compound C1=C(F)C=CC2=NN(CCOCCCl)C(I)=C21 OACWLLVFJAJSBC-UHFFFAOYSA-N 0.000 description 2
- ZTGGTKOXLNAJDL-UHFFFAOYSA-N 2-ethyl-3-iodo-5-methylindazole Chemical compound C1=CC(C)=CC2=C(I)N(CC)N=C21 ZTGGTKOXLNAJDL-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ZWCIANXPJYGVEM-UHFFFAOYSA-N 3-[(5-methyl-1-propylindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound C12=CC(C)=CC=C2N(CCC)N=C1NC1=CN=CC=C1C(O)=O ZWCIANXPJYGVEM-UHFFFAOYSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- RIOLWQLHCRJOIC-UHFFFAOYSA-N 3-iodo-1-propylindazole Chemical compound C1=CC=C2N(CCC)N=C(I)C2=C1 RIOLWQLHCRJOIC-UHFFFAOYSA-N 0.000 description 2
- JTLFYCKYWTYJGQ-UHFFFAOYSA-N 3-iodo-2,5-dimethylindazole Chemical compound C1=C(C)C=CC2=NN(C)C(I)=C21 JTLFYCKYWTYJGQ-UHFFFAOYSA-N 0.000 description 2
- MPGNCHMFUCTNAW-UHFFFAOYSA-N 3-iodo-2-methylindazole Chemical compound C1=CC=CC2=C(I)N(C)N=C21 MPGNCHMFUCTNAW-UHFFFAOYSA-N 0.000 description 2
- QJRJZDWBCPFRAN-UHFFFAOYSA-N 3-iodo-6-methoxy-2-methylindazole Chemical compound C1=C(OC)C=CC2=C(I)N(C)N=C21 QJRJZDWBCPFRAN-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- KAGGOMVMHLGTDI-UHFFFAOYSA-N 5-chloro-1-(3,3,3-trifluoropropyl)indol-3-amine Chemical compound C1=C(Cl)C=C2C(N)=CN(CCC(F)(F)F)C2=C1 KAGGOMVMHLGTDI-UHFFFAOYSA-N 0.000 description 2
- FWIUZCRZQRCDEM-UHFFFAOYSA-N 5-chloro-3-iodo-1-(2-pyrrolidin-1-ylethyl)indazole Chemical compound N1=C(I)C2=CC(Cl)=CC=C2N1CCN1CCCC1 FWIUZCRZQRCDEM-UHFFFAOYSA-N 0.000 description 2
- FEXCEYQBPHTNEJ-UHFFFAOYSA-N 5-chloro-3-iodo-2-methylindazole Chemical compound C1=CC(Cl)=CC2=C(I)N(C)N=C21 FEXCEYQBPHTNEJ-UHFFFAOYSA-N 0.000 description 2
- COCDVZRHARWGKI-UHFFFAOYSA-N 5-chloro-3-nitro-1h-indole Chemical compound C1=C(Cl)C=C2C([N+](=O)[O-])=CNC2=C1 COCDVZRHARWGKI-UHFFFAOYSA-N 0.000 description 2
- QKIVFQYKQUYJJL-UHFFFAOYSA-N 5-fluoro-3-iodo-1-(2-phenylethyl)indazole Chemical compound N1=C(I)C2=CC(F)=CC=C2N1CCC1=CC=CC=C1 QKIVFQYKQUYJJL-UHFFFAOYSA-N 0.000 description 2
- WHTIMQWVDSVLAA-UHFFFAOYSA-N 5-fluoro-3-iodo-1-(3-methoxypropyl)indazole Chemical compound FC1=CC=C2N(CCCOC)N=C(I)C2=C1 WHTIMQWVDSVLAA-UHFFFAOYSA-N 0.000 description 2
- NMKOEUOMKQUPGP-UHFFFAOYSA-N 5-fluoro-3-iodo-1-(oxolan-2-ylmethyl)indazole Chemical compound N1=C(I)C2=CC(F)=CC=C2N1CC1CCCO1 NMKOEUOMKQUPGP-UHFFFAOYSA-N 0.000 description 2
- TTZGSSNWSVGCLP-UHFFFAOYSA-N 5-fluoro-3-iodo-2-(2-phenylethyl)indazole Chemical compound IC1=C2C=C(F)C=CC2=NN1CCC1=CC=CC=C1 TTZGSSNWSVGCLP-UHFFFAOYSA-N 0.000 description 2
- GRCMLULLNYVGSI-UHFFFAOYSA-N 5-fluoro-3-iodo-2-(oxolan-2-ylmethyl)indazole Chemical compound IC1=C2C=C(F)C=CC2=NN1CC1CCCO1 GRCMLULLNYVGSI-UHFFFAOYSA-N 0.000 description 2
- UUONYJSODYVFPX-UHFFFAOYSA-N 5-fluoro-3-iodo-2-pentylindazole Chemical compound C1=CC(F)=CC2=C(I)N(CCCCC)N=C21 UUONYJSODYVFPX-UHFFFAOYSA-N 0.000 description 2
- WDNXQSDOIMZJTL-UHFFFAOYSA-N 5-fluoro-3-iodo-2-propylindazole Chemical compound C1=CC(F)=CC2=C(I)N(CCC)N=C21 WDNXQSDOIMZJTL-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 238000007125 Buchwald synthesis reaction Methods 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108010034791 Heterochromatin Proteins 0.000 description 2
- 101710160287 Heterochromatin protein 1 Proteins 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 102000058057 JmjC domain-containing Human genes 0.000 description 2
- 108700001203 JmjC domain-containing Proteins 0.000 description 2
- 102000016624 JmjC domains Human genes 0.000 description 2
- 108050006228 JmjC domains Proteins 0.000 description 2
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 2
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004458 heterochromatin Anatomy 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical group C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 101150076630 jhdm-1 gene Proteins 0.000 description 2
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- RMHAIWFFEFFZGC-UHFFFAOYSA-N methyl 3-[(5-fluoro-1-propylindol-3-yl)amino]pyridine-4-carboxylate Chemical compound C12=CC(F)=CC=C2N(CCC)C=C1NC1=CN=CC=C1C(=O)OC RMHAIWFFEFFZGC-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 230000019639 protein methylation Effects 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XDPCNPCKDGQBAN-SCSAIBSYSA-N (3r)-oxolan-3-ol Chemical compound O[C@@H]1CCOC1 XDPCNPCKDGQBAN-SCSAIBSYSA-N 0.000 description 1
- QPMSJEFZULFYTB-PGMHMLKASA-N (3r)-pyrrolidin-3-ol;hydrochloride Chemical compound Cl.O[C@@H]1CCNC1 QPMSJEFZULFYTB-PGMHMLKASA-N 0.000 description 1
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 description 1
- 125000006313 (C5-C8) alkyl group Chemical group 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- NLMVYUBGWZWUGB-UHFFFAOYSA-N 1,2-benzoxazol-3-amine Chemical compound C1=CC=C2C(N)=NOC2=C1 NLMVYUBGWZWUGB-UHFFFAOYSA-N 0.000 description 1
- NIIAVLFMTBTSNH-UHFFFAOYSA-N 1,2-dimethylquinolin-1-ium-4-amine;iodide Chemical compound [I-].C1=CC=CC2=[N+](C)C(C)=CC(N)=C21 NIIAVLFMTBTSNH-UHFFFAOYSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- IBODDUNKEPPBKW-UHFFFAOYSA-N 1,5-dibromopentane Chemical compound BrCCCCCBr IBODDUNKEPPBKW-UHFFFAOYSA-N 0.000 description 1
- BYNRFQHWZPUXBG-UHFFFAOYSA-N 1-(cyclobutylmethyl)-5-fluoro-3-iodoindazole Chemical compound N1=C(I)C2=CC(F)=CC=C2N1CC1CCC1 BYNRFQHWZPUXBG-UHFFFAOYSA-N 0.000 description 1
- UCRBHHWOZIQOIO-UHFFFAOYSA-N 1-(cyclopentylmethyl)-5-fluoro-3-iodoindazole Chemical compound N1=C(I)C2=CC(F)=CC=C2N1CC1CCCC1 UCRBHHWOZIQOIO-UHFFFAOYSA-N 0.000 description 1
- SIZHWSKQQPFGCP-UHFFFAOYSA-N 1-(cyclopropylmethyl)-5-fluoro-3-iodoindazole Chemical compound N1=C(I)C2=CC(F)=CC=C2N1CC1CC1 SIZHWSKQQPFGCP-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- PWMWNFMRSKOCEY-UHFFFAOYSA-N 1-Phenyl-1,2-ethanediol Chemical compound OCC(O)C1=CC=CC=C1 PWMWNFMRSKOCEY-UHFFFAOYSA-N 0.000 description 1
- HHUNTLFYAABJQO-UHFFFAOYSA-N 1-[2-(2-chloroethoxy)ethyl]-5-fluoro-3-iodoindazole Chemical compound FC1=CC=C2N(CCOCCCl)N=C(I)C2=C1 HHUNTLFYAABJQO-UHFFFAOYSA-N 0.000 description 1
- AYZJBQAWYDEGDQ-UHFFFAOYSA-N 1-benzyl-5-fluoro-3-iodoindazole Chemical compound N1=C(I)C2=CC(F)=CC=C2N1CC1=CC=CC=C1 AYZJBQAWYDEGDQ-UHFFFAOYSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- CEVMYGZHEJSOHZ-UHFFFAOYSA-N 1-bromo-3-methoxypropane Chemical compound COCCCBr CEVMYGZHEJSOHZ-UHFFFAOYSA-N 0.000 description 1
- NIDSRGCVYOEDFW-UHFFFAOYSA-N 1-bromo-4-chlorobutane Chemical compound ClCCCCBr NIDSRGCVYOEDFW-UHFFFAOYSA-N 0.000 description 1
- YZWKKMVJZFACSU-UHFFFAOYSA-N 1-bromopentane Chemical compound CCCCCBr YZWKKMVJZFACSU-UHFFFAOYSA-N 0.000 description 1
- VXPAELZPQNSMEW-UHFFFAOYSA-N 1-butan-2-yl-5-fluoro-3-iodoindazole Chemical compound FC1=CC=C2N(C(C)CC)N=C(I)C2=C1 VXPAELZPQNSMEW-UHFFFAOYSA-N 0.000 description 1
- XTIGGAHUZJWQMD-UHFFFAOYSA-N 1-chloro-2-methoxyethane Chemical compound COCCCl XTIGGAHUZJWQMD-UHFFFAOYSA-N 0.000 description 1
- HKMALOORHWPYAL-UHFFFAOYSA-N 1-cyclopentyl-5-fluoro-3-iodoindazole Chemical compound N1=C(I)C2=CC(F)=CC=C2N1C1CCCC1 HKMALOORHWPYAL-UHFFFAOYSA-N 0.000 description 1
- XUSMPXBHVZCNMU-UHFFFAOYSA-N 1-ethyl-3-iodo-5-methylindazole Chemical compound CC1=CC=C2N(CC)N=C(I)C2=C1 XUSMPXBHVZCNMU-UHFFFAOYSA-N 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 102100027833 14-3-3 protein sigma Human genes 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical class OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- KMNCMJBGDUZKRM-UHFFFAOYSA-N 2-(4-methylmorpholin-2-yl)ethanol Chemical compound CN1CCOC(CCO)C1 KMNCMJBGDUZKRM-UHFFFAOYSA-N 0.000 description 1
- VOHILFSOWRNVJJ-UHFFFAOYSA-N 2-(bromomethyl)oxolane Chemical compound BrCC1CCCO1 VOHILFSOWRNVJJ-UHFFFAOYSA-N 0.000 description 1
- HOHNARUBRMDHKE-UHFFFAOYSA-N 2-[2-(5-chloro-3-iodoindazol-1-yl)ethoxy]-n,n-dimethylethanamine Chemical compound ClC1=CC=C2N(CCOCCN(C)C)N=C(I)C2=C1 HOHNARUBRMDHKE-UHFFFAOYSA-N 0.000 description 1
- CPHGJNGEWTYZIL-UHFFFAOYSA-N 2-[2-(5-fluoro-3-iodoindazol-1-yl)ethoxy]-n,n-dimethylethanamine Chemical compound FC1=CC=C2N(CCOCCN(C)C)N=C(I)C2=C1 CPHGJNGEWTYZIL-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- UPSXAPQYNGXVBF-UHFFFAOYSA-N 2-bromobutane Chemical compound CCC(C)Br UPSXAPQYNGXVBF-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- YYVPZQADFREIFR-UHFFFAOYSA-N 3,3-difluoropyrrolidine;hydrochloride Chemical compound [Cl-].FC1(F)CC[NH2+]C1 YYVPZQADFREIFR-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- GSLDPHCBPBZJTH-UHFFFAOYSA-N 3-[(1,5-dimethylindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound C12=CC(C)=CC=C2N(C)N=C1NC1=CN=CC=C1C(O)=O GSLDPHCBPBZJTH-UHFFFAOYSA-N 0.000 description 1
- OXJMVTIHWYNOFO-UHFFFAOYSA-N 3-[(1,6-dimethylindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound N=1N(C)C2=CC(C)=CC=C2C=1NC1=CN=CC=C1C(O)=O OXJMVTIHWYNOFO-UHFFFAOYSA-N 0.000 description 1
- XPBGYJQDZOLQAL-UHFFFAOYSA-N 3-[(1-benzyl-5-fluoroindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC(C1=CC(F)=CC=C11)=NN1CC1=CC=CC=C1 XPBGYJQDZOLQAL-UHFFFAOYSA-N 0.000 description 1
- QXZXMNIQTVHMQP-UHFFFAOYSA-N 3-[(1-butan-2-yl-5-fluoroindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound C12=CC(F)=CC=C2N(C(C)CC)N=C1NC1=CN=CC=C1C(O)=O QXZXMNIQTVHMQP-UHFFFAOYSA-N 0.000 description 1
- LJHFNRZRNINLGH-UHFFFAOYSA-N 3-[(1-cyclopentyl-5-fluoroindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC(C1=CC(F)=CC=C11)=NN1C1CCCC1 LJHFNRZRNINLGH-UHFFFAOYSA-N 0.000 description 1
- HJYLZMOMYZSYOU-UHFFFAOYSA-N 3-[(1-ethyl-5-methylindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound C12=CC(C)=CC=C2N(CC)N=C1NC1=CN=CC=C1C(O)=O HJYLZMOMYZSYOU-UHFFFAOYSA-N 0.000 description 1
- CPZUCKVTDNNRCJ-UHFFFAOYSA-N 3-[(1-methylindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound C12=CC=CC=C2N(C)N=C1NC1=CN=CC=C1C(O)=O CPZUCKVTDNNRCJ-UHFFFAOYSA-N 0.000 description 1
- PDGFLQVBIRFKHM-UHFFFAOYSA-N 3-[(1-propylindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound C12=CC=CC=C2N(CCC)N=C1NC1=CN=CC=C1C(O)=O PDGFLQVBIRFKHM-UHFFFAOYSA-N 0.000 description 1
- XHLDZZFRSRZGNZ-UHFFFAOYSA-N 3-[(2-methylindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound CN1N=C2C=CC=CC2=C1NC1=CN=CC=C1C(O)=O XHLDZZFRSRZGNZ-UHFFFAOYSA-N 0.000 description 1
- MVLYGYPENISRGG-UHFFFAOYSA-N 3-[(4-fluoro-1-methylindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound C12=C(F)C=CC=C2N(C)N=C1NC1=CN=CC=C1C(O)=O MVLYGYPENISRGG-UHFFFAOYSA-N 0.000 description 1
- TXMBUJQSVXBAFZ-UHFFFAOYSA-N 3-[(5-chloro-1-methylindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound C12=CC(Cl)=CC=C2N(C)N=C1NC1=CN=CC=C1C(O)=O TXMBUJQSVXBAFZ-UHFFFAOYSA-N 0.000 description 1
- ASGLMUMSWBQYBM-UHFFFAOYSA-N 3-[(5-chloro-1-propylindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound C12=CC(Cl)=CC=C2N(CCC)N=C1NC1=CN=CC=C1C(O)=O ASGLMUMSWBQYBM-UHFFFAOYSA-N 0.000 description 1
- RWPUEFYTGNACRB-UHFFFAOYSA-N 3-[(5-cyano-1h-indol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC1=CNC2=CC=C(C#N)C=C12 RWPUEFYTGNACRB-UHFFFAOYSA-N 0.000 description 1
- SXBMYQHPOVFVHF-UHFFFAOYSA-N 3-[(5-fluoro-1-methylindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound C12=CC(F)=CC=C2N(C)N=C1NC1=CN=CC=C1C(O)=O SXBMYQHPOVFVHF-UHFFFAOYSA-N 0.000 description 1
- CAPANHTUNRFSGB-UHFFFAOYSA-N 3-[(5-fluoro-1-pentylindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound C12=CC(F)=CC=C2N(CCCCC)N=C1NC1=CN=CC=C1C(O)=O CAPANHTUNRFSGB-UHFFFAOYSA-N 0.000 description 1
- IDYSUPOPUILGCS-UHFFFAOYSA-N 3-[(5-fluoro-1-propylindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound C12=CC(F)=CC=C2N(CCC)N=C1NC1=CN=CC=C1C(O)=O IDYSUPOPUILGCS-UHFFFAOYSA-N 0.000 description 1
- FDILHQJCFKWROO-UHFFFAOYSA-N 3-[(5-fluoro-1-propylindol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound C12=CC(F)=CC=C2N(CCC)C=C1NC1=CN=CC=C1C(O)=O FDILHQJCFKWROO-UHFFFAOYSA-N 0.000 description 1
- LVURFDXVKLZEMI-UHFFFAOYSA-N 3-[(6-fluoro-1-methylindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound C12=CC=C(F)C=C2N(C)N=C1NC1=CN=CC=C1C(O)=O LVURFDXVKLZEMI-UHFFFAOYSA-N 0.000 description 1
- ATHMAOJGWSJVEU-UHFFFAOYSA-N 3-[(6-methoxy-1-methylindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound N=1N(C)C2=CC(OC)=CC=C2C=1NC1=CN=CC=C1C(O)=O ATHMAOJGWSJVEU-UHFFFAOYSA-N 0.000 description 1
- LWBSTDMGDQNQBE-UHFFFAOYSA-N 3-[(7-fluoro-1-propylindazol-3-yl)amino]pyridine-4-carboxylic acid Chemical compound C12=CC=CC(F)=C2N(CCC)N=C1NC1=CN=CC=C1C(O)=O LWBSTDMGDQNQBE-UHFFFAOYSA-N 0.000 description 1
- FKELVFOTUZGRLQ-UHFFFAOYSA-N 3-[[1-(2-methoxyethyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound C12=CC=CC=C2N(CCOC)N=C1NC1=CN=CC=C1C(O)=O FKELVFOTUZGRLQ-UHFFFAOYSA-N 0.000 description 1
- NYSUAXALBQGPDH-UHFFFAOYSA-N 3-[[1-[2-[2-(dimethylamino)ethoxy]ethyl]-5-fluoroindazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound C12=CC(F)=CC=C2N(CCOCCN(C)C)N=C1NC1=CN=CC=C1C(O)=O NYSUAXALBQGPDH-UHFFFAOYSA-N 0.000 description 1
- FCXTWOYKEXDPIW-UHFFFAOYSA-N 3-[[1-[2-[2-(dimethylamino)ethoxy]ethyl]indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound C12=CC=CC=C2N(CCOCCN(C)C)N=C1NC1=CN=CC=C1C(O)=O FCXTWOYKEXDPIW-UHFFFAOYSA-N 0.000 description 1
- COKQEBSDGZNRLI-UHFFFAOYSA-N 3-[[5-chloro-1-(2-pyrrolidin-1-ylethyl)indazol-3-yl]amino]-n-cyanopyridine-4-carboxamide Chemical compound N1=C(NC=2C(=CC=NC=2)C(=O)NC#N)C2=CC(Cl)=CC=C2N1CCN1CCCC1 COKQEBSDGZNRLI-UHFFFAOYSA-N 0.000 description 1
- KHVBTGDZMFHBJJ-UHFFFAOYSA-N 3-[[5-chloro-1-(2-pyrrolidin-1-ylethyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC(C1=CC(Cl)=CC=C11)=NN1CCN1CCCC1 KHVBTGDZMFHBJJ-UHFFFAOYSA-N 0.000 description 1
- RWMFBPHVUBQDQE-UHFFFAOYSA-N 3-[[5-chloro-1-(3,3,3-trifluoropropyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC1=NN(CCC(F)(F)F)C2=CC=C(Cl)C=C12 RWMFBPHVUBQDQE-UHFFFAOYSA-N 0.000 description 1
- WAMJDGIWWXXCGE-UHFFFAOYSA-N 3-[[5-chloro-1-(3,3,3-trifluoropropyl)indol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC1=CN(CCC(F)(F)F)C2=CC=C(Cl)C=C12 WAMJDGIWWXXCGE-UHFFFAOYSA-N 0.000 description 1
- CEQIRGOSROIKND-UHFFFAOYSA-N 3-[[5-chloro-1-(cyclopropylmethyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC(C1=CC(Cl)=CC=C11)=NN1CC1CC1 CEQIRGOSROIKND-UHFFFAOYSA-N 0.000 description 1
- BXDPZMNOFXDPHK-UHFFFAOYSA-N 3-[[5-chloro-1-(oxolan-3-yl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC(C1=CC(Cl)=CC=C11)=NN1C1COCC1 BXDPZMNOFXDPHK-UHFFFAOYSA-N 0.000 description 1
- UVNHWAUUTHBCHA-UHFFFAOYSA-N 3-[[5-chloro-1-[2-[2-(dimethylamino)ethoxy]ethyl]indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound C12=CC(Cl)=CC=C2N(CCOCCN(C)C)N=C1NC1=CN=CC=C1C(O)=O UVNHWAUUTHBCHA-UHFFFAOYSA-N 0.000 description 1
- GPQRBFHFXGPAFQ-UHFFFAOYSA-N 3-[[5-fluoro-1-(2,2,2-trifluoroethyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC1=NN(CC(F)(F)F)C2=CC=C(F)C=C12 GPQRBFHFXGPAFQ-UHFFFAOYSA-N 0.000 description 1
- XRGWWXOUILGFTI-UHFFFAOYSA-N 3-[[5-fluoro-1-(2-hydroxypropyl)indazol-3-yl]amino]-2-methylpyridine-4-carboxylic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)C)N=C1NC1=C(C)N=CC=C1C(O)=O XRGWWXOUILGFTI-UHFFFAOYSA-N 0.000 description 1
- NWYDAARTNRHROH-UHFFFAOYSA-N 3-[[5-fluoro-1-(2-hydroxypropyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)C)N=C1NC1=CN=CC=C1C(O)=O NWYDAARTNRHROH-UHFFFAOYSA-N 0.000 description 1
- SNMVREBHKJIHNN-UHFFFAOYSA-N 3-[[5-fluoro-1-(2-methylpropyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound C12=CC(F)=CC=C2N(CC(C)C)N=C1NC1=CN=CC=C1C(O)=O SNMVREBHKJIHNN-UHFFFAOYSA-N 0.000 description 1
- DUXQQAGIMQADPV-UHFFFAOYSA-N 3-[[5-fluoro-1-(2-phenylethyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC(C1=CC(F)=CC=C11)=NN1CCC1=CC=CC=C1 DUXQQAGIMQADPV-UHFFFAOYSA-N 0.000 description 1
- RWXZMWWDSPELBT-UHFFFAOYSA-N 3-[[5-fluoro-1-(2-piperidin-3-ylethyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC(C1=CC(F)=CC=C11)=NN1CCC1CNCCC1 RWXZMWWDSPELBT-UHFFFAOYSA-N 0.000 description 1
- HFQCUTRLHUHLRB-UHFFFAOYSA-N 3-[[5-fluoro-1-(2-pyrrolidin-1-ylethyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC(C1=CC(F)=CC=C11)=NN1CCN1CCCC1 HFQCUTRLHUHLRB-UHFFFAOYSA-N 0.000 description 1
- NJPHSBFEDZSMAZ-UHFFFAOYSA-N 3-[[5-fluoro-1-(3,3,3-trifluoro-2-hydroxypropyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)C(F)(F)F)N=C1NC1=CN=CC=C1C(O)=O NJPHSBFEDZSMAZ-UHFFFAOYSA-N 0.000 description 1
- MOGZWNQNKQFXNI-UHFFFAOYSA-N 3-[[5-fluoro-1-(3,3,3-trifluoropropyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC1=NN(CCC(F)(F)F)C2=CC=C(F)C=C12 MOGZWNQNKQFXNI-UHFFFAOYSA-N 0.000 description 1
- WVJOMVYKENYRIU-UHFFFAOYSA-N 3-[[5-fluoro-1-(3-hydroxypropyl)indazol-3-yl]amino]-2-methylpyridine-4-carboxylic acid Chemical compound CC1=NC=CC(C(O)=O)=C1NC1=NN(CCCO)C2=CC=C(F)C=C12 WVJOMVYKENYRIU-UHFFFAOYSA-N 0.000 description 1
- CGRMYBDLLLMQAP-UHFFFAOYSA-N 3-[[5-fluoro-1-(3-hydroxypropyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound C12=CC(F)=CC=C2N(CCCO)N=C1NC1=CN=CC=C1C(O)=O CGRMYBDLLLMQAP-UHFFFAOYSA-N 0.000 description 1
- HLYIHSPDESETDD-UHFFFAOYSA-N 3-[[5-fluoro-1-(3-methoxypropyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound C12=CC(F)=CC=C2N(CCCOC)N=C1NC1=CN=CC=C1C(O)=O HLYIHSPDESETDD-UHFFFAOYSA-N 0.000 description 1
- AEPRJEGBYCRNTO-UHFFFAOYSA-N 3-[[5-fluoro-1-(5-hydroxypentyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound C12=CC(F)=CC=C2N(CCCCCO)N=C1NC1=CN=CC=C1C(O)=O AEPRJEGBYCRNTO-UHFFFAOYSA-N 0.000 description 1
- RMBFTWHBPWJTQR-UHFFFAOYSA-N 3-[[5-fluoro-1-(oxan-3-yl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC(C1=CC(F)=CC=C11)=NN1C1COCCC1 RMBFTWHBPWJTQR-UHFFFAOYSA-N 0.000 description 1
- YFWMMWXAAXINTP-UHFFFAOYSA-N 3-[[5-fluoro-1-(oxan-4-yl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC(C1=CC(F)=CC=C11)=NN1C1CCOCC1 YFWMMWXAAXINTP-UHFFFAOYSA-N 0.000 description 1
- ZXVMZDZMKAVKLI-UHFFFAOYSA-N 3-[[5-fluoro-1-(oxolan-2-ylmethyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC(C1=CC(F)=CC=C11)=NN1CC1OCCC1 ZXVMZDZMKAVKLI-UHFFFAOYSA-N 0.000 description 1
- CLACBXJUUICJKS-UHFFFAOYSA-N 3-[[5-fluoro-1-(oxolan-3-yl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC(C1=CC(F)=CC=C11)=NN1C1COCC1 CLACBXJUUICJKS-UHFFFAOYSA-N 0.000 description 1
- HLHPSEPZDHRQDS-UHFFFAOYSA-N 3-[[5-fluoro-1-(oxolan-3-yl)indol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC(C1=CC(F)=CC=C11)=CN1C1COCC1 HLHPSEPZDHRQDS-UHFFFAOYSA-N 0.000 description 1
- DNOHWOWSEKJTNK-UHFFFAOYSA-N 3-[[5-fluoro-1-[2-(4-methylmorpholin-2-yl)ethyl]indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound C1N(C)CCOC1CCN1C2=CC=C(F)C=C2C(NC=2C(=CC=NC=2)C(O)=O)=N1 DNOHWOWSEKJTNK-UHFFFAOYSA-N 0.000 description 1
- QWHULRZVRSTPNH-UHFFFAOYSA-N 3-[[5-fluoro-1-[5-(methylamino)pentyl]indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound C12=CC(F)=CC=C2N(CCCCCNC)N=C1NC1=CN=CC=C1C(O)=O QWHULRZVRSTPNH-UHFFFAOYSA-N 0.000 description 1
- KTXTWMVOBPWQQA-UHFFFAOYSA-N 3-[[5-methyl-1-(3,3,3-trifluoropropyl)indazol-3-yl]amino]pyridine-4-carboxylic acid Chemical compound C12=CC(C)=CC=C2N(CCC(F)(F)F)N=C1NC1=CN=CC=C1C(O)=O KTXTWMVOBPWQQA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LKXVBYLJCJFZSC-UHFFFAOYSA-N 3-iodo-1-(oxolan-3-yl)-4,5,6,7-tetrahydroindazole Chemical compound C1=2CCCCC=2C(I)=NN1C1CCOC1 LKXVBYLJCJFZSC-UHFFFAOYSA-N 0.000 description 1
- OAQYCAYEBWRHLC-UHFFFAOYSA-N 3-iodo-1-methylindazole Chemical compound C1=CC=C2N(C)N=C(I)C2=C1 OAQYCAYEBWRHLC-UHFFFAOYSA-N 0.000 description 1
- CQOVTCKYTZSBBW-UHFFFAOYSA-N 3-iodo-1-propylindazole-5-carbonitrile Chemical compound N#CC1=CC=C2N(CCC)N=C(I)C2=C1 CQOVTCKYTZSBBW-UHFFFAOYSA-N 0.000 description 1
- WUXBWWWYWVYSTI-UHFFFAOYSA-N 3-iodo-2h-indazole-5-carbonitrile Chemical compound C1=C(C#N)C=C2C(I)=NNC2=C1 WUXBWWWYWVYSTI-UHFFFAOYSA-N 0.000 description 1
- AZHMCMMGUMQQHX-UHFFFAOYSA-N 3-iodo-4,5,6,7-tetrahydro-1h-indazole Chemical compound C1CCCC2=C1NN=C2I AZHMCMMGUMQQHX-UHFFFAOYSA-N 0.000 description 1
- BUSATCRMLGBYBV-UHFFFAOYSA-N 3-iodo-5-methyl-1-(3,3,3-trifluoropropyl)indazole Chemical compound CC1=CC=C2N(CCC(F)(F)F)N=C(I)C2=C1 BUSATCRMLGBYBV-UHFFFAOYSA-N 0.000 description 1
- BCMUAZAZFZEWAB-UHFFFAOYSA-N 3-iodo-5-methyl-1-propylindazole Chemical compound CC1=CC=C2N(CCC)N=C(I)C2=C1 BCMUAZAZFZEWAB-UHFFFAOYSA-N 0.000 description 1
- WPEGXAAVEVXKBA-UHFFFAOYSA-N 3-iodo-6-methoxy-1-methylindazole Chemical compound COC1=CC=C2C(I)=NN(C)C2=C1 WPEGXAAVEVXKBA-UHFFFAOYSA-N 0.000 description 1
- OHXDNTHWTHMKRG-UHFFFAOYSA-N 3-iodo-6-methoxy-2h-indazole Chemical compound COC1=CC=C2C(I)=NNC2=C1 OHXDNTHWTHMKRG-UHFFFAOYSA-N 0.000 description 1
- LCBIAXZUZKSIHA-UHFFFAOYSA-N 3-iodo-6-methyl-2h-indazole Chemical compound CC1=CC=C2C(I)=NNC2=C1 LCBIAXZUZKSIHA-UHFFFAOYSA-N 0.000 description 1
- YJVYLWHZQZNPNJ-UHFFFAOYSA-N 3-iodo-7-methyl-1-propylindazole Chemical compound C1=CC(C)=C2N(CCC)N=C(I)C2=C1 YJVYLWHZQZNPNJ-UHFFFAOYSA-N 0.000 description 1
- WYUIOANIHMLVPU-UHFFFAOYSA-N 3-iodo-7-methyl-2h-indazole Chemical compound CC1=CC=CC2=C1NN=C2I WYUIOANIHMLVPU-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XTJZBCBHCPQASK-UHFFFAOYSA-N 4,4-difluorocyclohexan-1-ol Chemical compound OC1CCC(F)(F)CC1 XTJZBCBHCPQASK-UHFFFAOYSA-N 0.000 description 1
- MJOUJKDTBGXKIU-UHFFFAOYSA-N 4,4-difluoropiperidine Chemical compound FC1(F)CCNCC1 MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 1
- GDSQTWDUCDSZEY-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indazole Chemical compound C1CCCC2=C1C=NN2 GDSQTWDUCDSZEY-UHFFFAOYSA-N 0.000 description 1
- ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 1
- WVUYQAYIJMGTOW-UHFFFAOYSA-N 4-(5-fluoro-3-iodoindazol-1-yl)-n,n-dimethylbutan-1-amine Chemical compound FC1=CC=C2N(CCCCN(C)C)N=C(I)C2=C1 WVUYQAYIJMGTOW-UHFFFAOYSA-N 0.000 description 1
- RPUJAOFSZSEVPC-UHFFFAOYSA-N 4-chlorobut-2-yn-1-ol Chemical compound OCC#CCCl RPUJAOFSZSEVPC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- QKOXHOSIONDOLA-UHFFFAOYSA-N 4-fluoro-1-methylindazol-3-amine Chemical compound C1=CC=C2N(C)N=C(N)C2=C1F QKOXHOSIONDOLA-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- ZGELOSGIRXWWBV-UHFFFAOYSA-N 5-(5-fluoro-3-iodoindazol-1-yl)-n,n-dimethylpentan-1-amine Chemical compound FC1=CC=C2N(CCCCCN(C)C)N=C(I)C2=C1 ZGELOSGIRXWWBV-UHFFFAOYSA-N 0.000 description 1
- YZIDCOYTJNFSOY-UHFFFAOYSA-N 5-(5-fluoro-3-iodoindazol-1-yl)-n-methylpentan-1-amine Chemical compound FC1=CC=C2N(CCCCCNC)N=C(I)C2=C1 YZIDCOYTJNFSOY-UHFFFAOYSA-N 0.000 description 1
- STVHMYNPQCLUNJ-UHFFFAOYSA-N 5-bromo-1h-indazole Chemical compound BrC1=CC=C2NN=CC2=C1 STVHMYNPQCLUNJ-UHFFFAOYSA-N 0.000 description 1
- SSSQDXQFCLEGPN-UHFFFAOYSA-N 5-chloro-1-(oxolan-3-yl)indazol-3-amine Chemical compound C12=CC=C(Cl)C=C2C(N)=NN1C1CCOC1 SSSQDXQFCLEGPN-UHFFFAOYSA-N 0.000 description 1
- MYTGFBZJLDLWQG-UHFFFAOYSA-N 5-chloro-1h-indole Chemical compound ClC1=CC=C2NC=CC2=C1 MYTGFBZJLDLWQG-UHFFFAOYSA-N 0.000 description 1
- SJFXZYOMPUNQRL-UHFFFAOYSA-N 5-chloro-3-iodo-1-(3,3,3-trifluoropropyl)indazole Chemical compound ClC1=CC=C2N(CCC(F)(F)F)N=C(I)C2=C1 SJFXZYOMPUNQRL-UHFFFAOYSA-N 0.000 description 1
- DZQSEJIIEJWGJH-UHFFFAOYSA-N 5-chloro-3-iodo-1-methylindazole Chemical compound ClC1=CC=C2N(C)N=C(I)C2=C1 DZQSEJIIEJWGJH-UHFFFAOYSA-N 0.000 description 1
- AOPWHJQYAQAEEL-UHFFFAOYSA-N 5-chloro-3-iodo-1-propylindazole Chemical compound ClC1=CC=C2N(CCC)N=C(I)C2=C1 AOPWHJQYAQAEEL-UHFFFAOYSA-N 0.000 description 1
- KSRPRFYOIRHWGQ-UHFFFAOYSA-N 5-chloro-3-nitro-1-(3,3,3-trifluoropropyl)indole Chemical compound C1=C(Cl)C=C2C([N+](=O)[O-])=CN(CCC(F)(F)F)C2=C1 KSRPRFYOIRHWGQ-UHFFFAOYSA-N 0.000 description 1
- LPLUXDHRFBSFFK-UHFFFAOYSA-N 5-fluoro-1-(oxolan-3-yl)indol-3-amine Chemical compound C12=CC=C(F)C=C2C(N)=CN1C1CCOC1 LPLUXDHRFBSFFK-UHFFFAOYSA-N 0.000 description 1
- XCPNGUIESXJDEW-UHFFFAOYSA-N 5-fluoro-1-methylindazol-3-amine Chemical compound FC1=CC=C2N(C)N=C(N)C2=C1 XCPNGUIESXJDEW-UHFFFAOYSA-N 0.000 description 1
- HMZSOZYJDSLCFZ-UHFFFAOYSA-N 5-fluoro-1-propylindol-3-amine Chemical compound FC1=CC=C2N(CCC)C=C(N)C2=C1 HMZSOZYJDSLCFZ-UHFFFAOYSA-N 0.000 description 1
- ZIYGFCKNLIOOEH-UHFFFAOYSA-N 5-fluoro-3-iodo-1-(2,2,2-trifluoroethyl)indazole Chemical compound FC1=CC=C2N(CC(F)(F)F)N=C(I)C2=C1 ZIYGFCKNLIOOEH-UHFFFAOYSA-N 0.000 description 1
- PKWMMKLLZOHRLC-UHFFFAOYSA-N 5-fluoro-3-iodo-1-(2-methylpropyl)indazole Chemical compound FC1=CC=C2N(CC(C)C)N=C(I)C2=C1 PKWMMKLLZOHRLC-UHFFFAOYSA-N 0.000 description 1
- XWIZNHDFQVMHEB-UHFFFAOYSA-N 5-fluoro-3-iodo-1-(2-pyrrolidin-1-ylethyl)indazole Chemical compound N1=C(I)C2=CC(F)=CC=C2N1CCN1CCCC1 XWIZNHDFQVMHEB-UHFFFAOYSA-N 0.000 description 1
- UUUGSPBTPWHJQW-UHFFFAOYSA-N 5-fluoro-3-iodo-1-(3,3,3-trifluoropropyl)indazole Chemical compound FC1=CC=C2N(CCC(F)(F)F)N=C(I)C2=C1 UUUGSPBTPWHJQW-UHFFFAOYSA-N 0.000 description 1
- SAQNBJFZMHGUPI-UHFFFAOYSA-N 5-fluoro-3-iodo-1-(oxan-3-yl)indazole Chemical compound N1=C(I)C2=CC(F)=CC=C2N1C1CCCOC1 SAQNBJFZMHGUPI-UHFFFAOYSA-N 0.000 description 1
- OQKHMGNSZPEHDM-UHFFFAOYSA-N 5-fluoro-3-iodo-1-(oxan-4-yl)indazole Chemical compound N1=C(I)C2=CC(F)=CC=C2N1C1CCOCC1 OQKHMGNSZPEHDM-UHFFFAOYSA-N 0.000 description 1
- NSRJTSCSPNBJGH-UHFFFAOYSA-N 5-fluoro-3-iodo-1-pentylindazole Chemical compound FC1=CC=C2N(CCCCC)N=C(I)C2=C1 NSRJTSCSPNBJGH-UHFFFAOYSA-N 0.000 description 1
- FUVZMTVKAUVOAA-UHFFFAOYSA-N 5-fluoro-3-iodo-1-propylindazole Chemical compound FC1=CC=C2N(CCC)N=C(I)C2=C1 FUVZMTVKAUVOAA-UHFFFAOYSA-N 0.000 description 1
- JTEIKHMZBVKCMQ-UHFFFAOYSA-N 5-fluoro-3-iodo-2-(3-methoxypropyl)indazole Chemical compound C1=CC(F)=CC2=C(I)N(CCCOC)N=C21 JTEIKHMZBVKCMQ-UHFFFAOYSA-N 0.000 description 1
- LFDCGVYZCYSMIW-UHFFFAOYSA-N 5-fluoro-3-nitro-1-(oxolan-3-yl)indole Chemical compound C12=CC=C(F)C=C2C([N+](=O)[O-])=CN1C1CCOC1 LFDCGVYZCYSMIW-UHFFFAOYSA-N 0.000 description 1
- OCOSMMCIWLONOC-UHFFFAOYSA-N 5-fluoro-3-nitro-1-propylindole Chemical compound FC1=CC=C2N(CCC)C=C([N+]([O-])=O)C2=C1 OCOSMMCIWLONOC-UHFFFAOYSA-N 0.000 description 1
- ODFFPRGJZRXNHZ-UHFFFAOYSA-N 5-fluoroindole Chemical compound FC1=CC=C2NC=CC2=C1 ODFFPRGJZRXNHZ-UHFFFAOYSA-N 0.000 description 1
- JZCSIHPIMFUXRA-UHFFFAOYSA-N 7-fluoro-3-iodo-1-propylindazole Chemical compound C1=CC(F)=C2N(CCC)N=C(I)C2=C1 JZCSIHPIMFUXRA-UHFFFAOYSA-N 0.000 description 1
- XXFFUCLHYAPZRP-UHFFFAOYSA-N 7-fluoro-3-iodo-2-propylindazole Chemical compound FC1=CC=CC2=C(I)N(CCC)N=C21 XXFFUCLHYAPZRP-UHFFFAOYSA-N 0.000 description 1
- NZLJQLITHWOQBC-UHFFFAOYSA-N 7-fluoro-3-iodo-2h-indazole Chemical compound FC1=CC=CC2=C1NN=C2I NZLJQLITHWOQBC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100035888 Caveolin-1 Human genes 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Substances CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 102100035864 Histone lysine demethylase PHF8 Human genes 0.000 description 1
- 101000723509 Homo sapiens 14-3-3 protein sigma Proteins 0.000 description 1
- 101000715467 Homo sapiens Caveolin-1 Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101001000378 Homo sapiens Histone lysine demethylase PHF8 Proteins 0.000 description 1
- 101000613958 Homo sapiens Lysine-specific demethylase 2A Proteins 0.000 description 1
- 101000613629 Homo sapiens Lysine-specific demethylase 4B Proteins 0.000 description 1
- 101001088895 Homo sapiens Lysine-specific demethylase 4D Proteins 0.000 description 1
- 101001088900 Homo sapiens Lysine-specific demethylase 4E Proteins 0.000 description 1
- 101001088887 Homo sapiens Lysine-specific demethylase 5C Proteins 0.000 description 1
- 101000692954 Homo sapiens Lysine-specific demethylase PHF2 Proteins 0.000 description 1
- 101001056567 Homo sapiens Protein Jumonji Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 101150086476 KDM5B gene Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100040598 Lysine-specific demethylase 2A Human genes 0.000 description 1
- 102100040860 Lysine-specific demethylase 4B Human genes 0.000 description 1
- 102100033231 Lysine-specific demethylase 4D Human genes 0.000 description 1
- 102100033232 Lysine-specific demethylase 4E Human genes 0.000 description 1
- 102100033249 Lysine-specific demethylase 5C Human genes 0.000 description 1
- 102100026395 Lysine-specific demethylase PHF2 Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010073150 Multiple endocrine neoplasia Type 1 Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- LYXFCGCYJQCSRL-UHFFFAOYSA-N OOSO Chemical compound OOSO LYXFCGCYJQCSRL-UHFFFAOYSA-N 0.000 description 1
- 102100027069 Odontogenic ameloblast-associated protein Human genes 0.000 description 1
- 101710091533 Odontogenic ameloblast-associated protein Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 240000002426 Persea americana var. drymifolia Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100025733 Protein Jumonji Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010021119 Trichosanthin Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 150000001484 arginines Chemical class 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- FLHFTXCMKFVKRP-UHFFFAOYSA-N bromomethylcyclobutane Chemical compound BrCC1CCC1 FLHFTXCMKFVKRP-UHFFFAOYSA-N 0.000 description 1
- XYZUWOHEILWUID-UHFFFAOYSA-N bromomethylcyclopentane Chemical compound BrCC1CCCC1 XYZUWOHEILWUID-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- ILAJWURWJKXJPW-UHFFFAOYSA-N butanedioic acid;octanedioic acid Chemical class OC(=O)CCC(O)=O.OC(=O)CCCCCCC(O)=O ILAJWURWJKXJPW-UHFFFAOYSA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 230000019975 dosage compensation by inactivation of X chromosome Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- LJLFQFGLXKIDNE-ZDUSSCGKSA-N ethyl 3-[[5-fluoro-1-[(3s)-pyrrolidin-3-yl]indazol-3-yl]amino]pyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC=C1NC(C1=CC(F)=CC=C11)=NN1[C@@H]1CNCC1 LJLFQFGLXKIDNE-ZDUSSCGKSA-N 0.000 description 1
- PKRRDTKZJZTYFC-UHFFFAOYSA-N ethyl 3-[[5-fluoro-1-[2-(4-methylmorpholin-2-yl)ethyl]indazol-3-yl]amino]pyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC=C1NC(C1=CC(F)=CC=C11)=NN1CCC1OCCN(C)C1 PKRRDTKZJZTYFC-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical group C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 102000033785 histone binding proteins Human genes 0.000 description 1
- 108091009732 histone binding proteins Proteins 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical class CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- ICKYUZXLMKMMBE-UHFFFAOYSA-N methyl 3-[(1-cyclopentyl-5-fluoroindazol-3-yl)amino]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1NC(C1=CC(F)=CC=C11)=NN1C1CCCC1 ICKYUZXLMKMMBE-UHFFFAOYSA-N 0.000 description 1
- QKQCKNIQDOCNDM-UHFFFAOYSA-N methyl 3-[(1-ethyl-5-methylindazol-3-yl)amino]pyridine-4-carboxylate Chemical compound C12=CC(C)=CC=C2N(CC)N=C1NC1=CN=CC=C1C(=O)OC QKQCKNIQDOCNDM-UHFFFAOYSA-N 0.000 description 1
- WVNKUJRSIXRDDB-UHFFFAOYSA-N methyl 3-[(1-methylindazol-3-yl)amino]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1NC1=NN(C)C2=CC=CC=C12 WVNKUJRSIXRDDB-UHFFFAOYSA-N 0.000 description 1
- XEHAGRMRZOSQSC-UHFFFAOYSA-N methyl 3-[(1-propylindazol-3-yl)amino]pyridine-4-carboxylate Chemical compound C12=CC=CC=C2N(CCC)N=C1NC1=CN=CC=C1C(=O)OC XEHAGRMRZOSQSC-UHFFFAOYSA-N 0.000 description 1
- ILUWPNISQKXJOF-UHFFFAOYSA-N methyl 3-[(5-chloro-1-methylindazol-3-yl)amino]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1NC1=NN(C)C2=CC=C(Cl)C=C12 ILUWPNISQKXJOF-UHFFFAOYSA-N 0.000 description 1
- UDGYOIKQSBWDNQ-UHFFFAOYSA-N methyl 3-[(5-cyano-1h-indol-3-yl)amino]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1NC1=CNC2=CC=C(C#N)C=C12 UDGYOIKQSBWDNQ-UHFFFAOYSA-N 0.000 description 1
- KYQSKXCPDVMUCG-UHFFFAOYSA-N methyl 3-[(5-fluoro-1-pentylindazol-3-yl)amino]pyridine-4-carboxylate Chemical compound C12=CC(F)=CC=C2N(CCCCC)N=C1NC1=CN=CC=C1C(=O)OC KYQSKXCPDVMUCG-UHFFFAOYSA-N 0.000 description 1
- CABXJDJGTYQRCB-UHFFFAOYSA-N methyl 3-[(7-fluoro-1-propylindazol-3-yl)amino]pyridine-4-carboxylate Chemical compound C12=CC=CC(F)=C2N(CCC)N=C1NC1=CN=CC=C1C(=O)OC CABXJDJGTYQRCB-UHFFFAOYSA-N 0.000 description 1
- FLCSVBOXZJZQBW-UHFFFAOYSA-N methyl 3-[(7-methyl-1-propylindazol-3-yl)amino]pyridine-4-carboxylate Chemical compound C12=CC=CC(C)=C2N(CCC)N=C1NC1=CN=CC=C1C(=O)OC FLCSVBOXZJZQBW-UHFFFAOYSA-N 0.000 description 1
- DUNOQGIBYUYNJD-UHFFFAOYSA-N methyl 3-[[1-[2-[2-(dimethylamino)ethoxy]ethyl]-5-fluoroindazol-3-yl]amino]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1NC1=NN(CCOCCN(C)C)C2=CC=C(F)C=C12 DUNOQGIBYUYNJD-UHFFFAOYSA-N 0.000 description 1
- UOPYHIXOADESLE-UHFFFAOYSA-N methyl 3-[[1-[2-[2-(dimethylamino)ethoxy]ethyl]indazol-3-yl]amino]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1NC1=NN(CCOCCN(C)C)C2=CC=CC=C12 UOPYHIXOADESLE-UHFFFAOYSA-N 0.000 description 1
- HYMIKZFINVLJNO-UHFFFAOYSA-N methyl 3-[[5-chloro-1-(2-pyrrolidin-1-ylethyl)indazol-3-yl]amino]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1NC(C1=CC(Cl)=CC=C11)=NN1CCN1CCCC1 HYMIKZFINVLJNO-UHFFFAOYSA-N 0.000 description 1
- ZOIHAMUEWSHMPR-UHFFFAOYSA-N methyl 3-[[5-chloro-1-[2-[2-(dimethylamino)ethoxy]ethyl]indazol-3-yl]amino]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1NC1=NN(CCOCCN(C)C)C2=CC=C(Cl)C=C12 ZOIHAMUEWSHMPR-UHFFFAOYSA-N 0.000 description 1
- KWAQXZRQVXBKSI-UHFFFAOYSA-N methyl 3-[[5-fluoro-1-(2-piperidin-3-ylethyl)indazol-3-yl]amino]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1NC(C1=CC(F)=CC=C11)=NN1CCC1CNCCC1 KWAQXZRQVXBKSI-UHFFFAOYSA-N 0.000 description 1
- XVTVEJMQMGOBQC-UHFFFAOYSA-N methyl 3-[[5-fluoro-1-(2-pyrrolidin-1-ylethyl)indazol-3-yl]amino]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1NC(C1=CC(F)=CC=C11)=NN1CCN1CCCC1 XVTVEJMQMGOBQC-UHFFFAOYSA-N 0.000 description 1
- FFNQLYSHQFSBIW-UHFFFAOYSA-N methyl 3-[[5-fluoro-1-[5-(methylamino)pentyl]indazol-3-yl]amino]pyridine-4-carboxylate Chemical compound C12=CC(F)=CC=C2N(CCCCCNC)N=C1NC1=CN=CC=C1C(=O)OC FFNQLYSHQFSBIW-UHFFFAOYSA-N 0.000 description 1
- MCEBXXSZFFMJLM-UHFFFAOYSA-N methyl 3-amino-4-bromo-2-nitrobenzoate Chemical compound COC(=O)C1=CC=C(Br)C(N)=C1[N+]([O-])=O MCEBXXSZFFMJLM-UHFFFAOYSA-N 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical class COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- IPIZDZPMQISFFX-AWQFTUOYSA-N n'-[(e)-pyridin-3-ylmethylideneamino]-n-[3-(trifluoromethyl)phenyl]oxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C(=O)N\N=C\C=2C=NC=CC=2)=C1 IPIZDZPMQISFFX-AWQFTUOYSA-N 0.000 description 1
- NOUUUQMKVOUUNR-UHFFFAOYSA-N n,n'-diphenylethane-1,2-diamine Chemical compound C=1C=CC=CC=1NCCNC1=CC=CC=C1 NOUUUQMKVOUUNR-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- AXCZGZNCDYAGSY-UHFFFAOYSA-N n-cyano-3-[[5-fluoro-1-(2-pyrrolidin-1-ylethyl)indazol-3-yl]amino]pyridine-4-carboxamide Chemical compound N1=C(NC=2C(=CC=NC=2)C(=O)NC#N)C2=CC(F)=CC=C2N1CCN1CCCC1 AXCZGZNCDYAGSY-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Chemical group C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical class CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000003901 oxalic acid esters Chemical class 0.000 description 1
- BHDLTOUYJMTTTM-UHFFFAOYSA-N oxan-3-ol Chemical compound OC1CCCOC1 BHDLTOUYJMTTTM-UHFFFAOYSA-N 0.000 description 1
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003899 tartaric acid esters Chemical class 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- MDHZNBDRDJQKNA-UHFFFAOYSA-N tert-butyl 3-[2-(5-fluoro-3-iodoindazol-1-yl)ethyl]piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC1CCN1C2=CC=C(F)C=C2C(I)=N1 MDHZNBDRDJQKNA-UHFFFAOYSA-N 0.000 description 1
- NMBHLHINPZVQIR-UHFFFAOYSA-N tert-butyl-(5-chloropentoxy)-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCCCCl NMBHLHINPZVQIR-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261739521P | 2012-12-19 | 2012-12-19 | |
| US61/739,521 | 2012-12-19 | ||
| US201361792930P | 2013-03-15 | 2013-03-15 | |
| US61/792,930 | 2013-03-15 | ||
| PCT/US2013/076666 WO2014100463A1 (en) | 2012-12-19 | 2013-12-19 | Histone demethylase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013361255A1 AU2013361255A1 (en) | 2015-07-09 |
| AU2013361255B2 true AU2013361255B2 (en) | 2017-01-05 |
Family
ID=50931614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013361255A Ceased AU2013361255B2 (en) | 2012-12-19 | 2013-12-19 | Histone demethylase inhibitors |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9617242B2 (https=) |
| EP (1) | EP2934145B1 (https=) |
| JP (1) | JP6256772B2 (https=) |
| AU (1) | AU2013361255B2 (https=) |
| CA (1) | CA2895355A1 (https=) |
| CY (1) | CY1119901T1 (https=) |
| DK (1) | DK2934145T3 (https=) |
| ES (1) | ES2658597T3 (https=) |
| HR (1) | HRP20180067T1 (https=) |
| HU (1) | HUE037312T2 (https=) |
| LT (1) | LT2934145T (https=) |
| PL (1) | PL2934145T3 (https=) |
| PT (1) | PT2934145T (https=) |
| RS (1) | RS56821B1 (https=) |
| SI (1) | SI2934145T1 (https=) |
| SM (1) | SMT201800070T1 (https=) |
| WO (1) | WO2014100463A1 (https=) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2877570T3 (es) | 2012-08-22 | 2021-11-17 | Univ Cornell | Métodos para inhibir fascina |
| DK2903968T3 (en) | 2012-10-02 | 2017-01-30 | Gilead Sciences Inc | INHIBITORS OF HISTON DEMETHYLASES |
| SMT201800070T1 (it) | 2012-12-19 | 2018-03-08 | Celgene Quanticel Res Inc | Inibiorti di istone demetilasi |
| BR112015014968A2 (pt) | 2012-12-21 | 2017-07-11 | Quanticel Pharmaceuticals Inc | inibidores de histona-desmetilase |
| PE20151667A1 (es) | 2013-02-27 | 2015-11-27 | Epitherapeutics Aps | Inhibidores de histona desmetilasas |
| US9738637B2 (en) | 2013-03-12 | 2017-08-22 | Celgene Quantical Research, Inc. | Histone demethylase inhibitors |
| KR20150130491A (ko) | 2013-03-13 | 2015-11-23 | 제넨테크, 인크. | 피라졸로 화합물 및 그것의 용도 |
| US9573946B2 (en) | 2014-02-20 | 2017-02-21 | Novita Pharmaceuticals, Inc. | Compounds and methods for inhibiting fascin |
| SI3160952T1 (sl) * | 2014-06-25 | 2021-07-30 | Celgene Quanticel Research, Inc. | Zaviralci histon demetilaz |
| SG11201701182VA (en) | 2014-08-27 | 2017-03-30 | Gilead Sciences Inc | Compounds and methods for inhibiting histone demethylases |
| EP3194387B1 (en) | 2014-09-17 | 2019-07-31 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| ES2910226T3 (es) | 2014-09-17 | 2022-05-12 | Celgene Quanticel Res Inc | Inhibidores de desmetilasa de histonas |
| US10030017B2 (en) | 2014-09-17 | 2018-07-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| WO2017117154A1 (en) * | 2015-12-28 | 2017-07-06 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN105601555B (zh) * | 2016-03-14 | 2018-07-31 | 苏州大学 | 一种制备硝基吲哚衍生物的方法 |
| EP3430008B1 (en) * | 2016-03-15 | 2022-05-18 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EA201892375A1 (ru) | 2016-05-27 | 2019-08-30 | Джилид Сайэнс, Инк. | Способы лечения инфекций, вызываемых вирусом гепатита b |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| WO2018073828A1 (en) * | 2016-10-20 | 2018-04-26 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Dna primase and gyrase inhibitors |
| TW202510891A (zh) | 2017-01-31 | 2025-03-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| UY37581A (es) | 2017-02-02 | 2018-08-31 | Gilead Sciences Inc | Compuestos para el tratamiento de la infección por virus de la hepatitis b |
| WO2018149986A1 (en) * | 2017-02-16 | 2018-08-23 | Oryzon Genomics, S.A. | 2-(bicyclo-heteroaryl)-isonicotinic derivatives as histone demethylase inhibitors |
| EP3600301B1 (en) | 2017-03-30 | 2024-07-03 | Albert-Ludwigs-Universität Freiburg | Kdm4 inhibitors |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| DK4037708T3 (da) | 2019-09-30 | 2024-09-30 | Gilead Sciences Inc | HBV-vacciner og fremgangsmåder til at behandle HBV |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| EP4192474B1 (en) | 2020-08-07 | 2025-09-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| TW202430151A (zh) | 2022-11-21 | 2024-08-01 | 日商日本新藥股份有限公司 | 作為ddr1激酶抑制劑之化合物及醫藥 |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002074388A1 (en) * | 2001-03-19 | 2002-09-26 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| US20040110956A1 (en) * | 2002-09-05 | 2004-06-10 | Dominique Lesuisse | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them |
| US20080070960A1 (en) * | 2005-02-22 | 2008-03-20 | Aventis Pharma S.A. | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer |
| US20110237590A1 (en) * | 2008-11-28 | 2011-09-29 | Takahiro Kitamura | Pyridine-3-carboxyamide derivative |
| WO2011140325A1 (en) * | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| WO2012118812A2 (en) * | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US8299057B2 (en) * | 2007-07-20 | 2012-10-30 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| AU2007275653B2 (en) * | 2006-07-20 | 2010-12-23 | Amgen Inc. | Benzo(d) isoxazole derivatives as c-kit tyrosine kinase inhibitors for the treatment of disorders associated with the over production of histamine |
| SMT201800070T1 (it) | 2012-12-19 | 2018-03-08 | Celgene Quanticel Res Inc | Inibiorti di istone demetilasi |
-
2013
- 2013-12-19 SM SM20180070T patent/SMT201800070T1/it unknown
- 2013-12-19 SI SI201330913T patent/SI2934145T1/en unknown
- 2013-12-19 LT LTEP13866465.1T patent/LT2934145T/lt unknown
- 2013-12-19 HU HUE13866465A patent/HUE037312T2/hu unknown
- 2013-12-19 RS RS20180071A patent/RS56821B1/sr unknown
- 2013-12-19 CA CA2895355A patent/CA2895355A1/en not_active Abandoned
- 2013-12-19 JP JP2015549728A patent/JP6256772B2/ja not_active Expired - Fee Related
- 2013-12-19 ES ES13866465.1T patent/ES2658597T3/es active Active
- 2013-12-19 US US14/653,818 patent/US9617242B2/en active Active
- 2013-12-19 US US14/134,989 patent/US8969343B2/en active Active
- 2013-12-19 DK DK13866465.1T patent/DK2934145T3/en active
- 2013-12-19 EP EP13866465.1A patent/EP2934145B1/en active Active
- 2013-12-19 PT PT138664651T patent/PT2934145T/pt unknown
- 2013-12-19 WO PCT/US2013/076666 patent/WO2014100463A1/en not_active Ceased
- 2013-12-19 PL PL13866465T patent/PL2934145T3/pl unknown
- 2013-12-19 HR HRP20180067TT patent/HRP20180067T1/hr unknown
- 2013-12-19 AU AU2013361255A patent/AU2013361255B2/en not_active Ceased
-
2017
- 2017-03-01 US US15/446,996 patent/US10040779B2/en active Active
-
2018
- 2018-02-09 CY CY20181100164T patent/CY1119901T1/el unknown
- 2018-06-29 US US16/024,452 patent/US10336727B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002074388A1 (en) * | 2001-03-19 | 2002-09-26 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| US20040110956A1 (en) * | 2002-09-05 | 2004-06-10 | Dominique Lesuisse | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them |
| US20080070960A1 (en) * | 2005-02-22 | 2008-03-20 | Aventis Pharma S.A. | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer |
| US8299057B2 (en) * | 2007-07-20 | 2012-10-30 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
| US20110237590A1 (en) * | 2008-11-28 | 2011-09-29 | Takahiro Kitamura | Pyridine-3-carboxyamide derivative |
| WO2011140325A1 (en) * | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| WO2012118812A2 (en) * | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| US20170174656A1 (en) | 2017-06-22 |
| HUE037312T2 (hu) | 2018-08-28 |
| HRP20180067T1 (hr) | 2018-02-23 |
| AU2013361255A1 (en) | 2015-07-09 |
| US9617242B2 (en) | 2017-04-11 |
| PT2934145T (pt) | 2018-02-13 |
| ES2658597T3 (es) | 2018-03-12 |
| CY1119901T1 (el) | 2018-06-27 |
| US20160060247A1 (en) | 2016-03-03 |
| CA2895355A1 (en) | 2014-06-26 |
| WO2014100463A1 (en) | 2014-06-26 |
| EP2934145A4 (en) | 2016-06-29 |
| US20180305336A1 (en) | 2018-10-25 |
| LT2934145T (lt) | 2018-02-26 |
| US8969343B2 (en) | 2015-03-03 |
| US10040779B2 (en) | 2018-08-07 |
| SI2934145T1 (en) | 2018-03-30 |
| US10336727B2 (en) | 2019-07-02 |
| SMT201800070T1 (it) | 2018-03-08 |
| US20140171432A1 (en) | 2014-06-19 |
| DK2934145T3 (en) | 2018-02-05 |
| RS56821B1 (sr) | 2018-04-30 |
| JP6256772B2 (ja) | 2018-01-10 |
| PL2934145T3 (pl) | 2018-04-30 |
| JP2016503799A (ja) | 2016-02-08 |
| EP2934145A1 (en) | 2015-10-28 |
| EP2934145B1 (en) | 2017-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013361255B2 (en) | Histone demethylase inhibitors | |
| JP6663866B2 (ja) | リジン特異的なデメチラーゼ−１の阻害剤 | |
| CN106660987B (zh) | 赖氨酸特异性脱甲基酶-1的抑制剂 | |
| AU2014249050B2 (en) | Histone dementhylase inhibitors | |
| CN106659914B (zh) | 赖氨酸特异性脱甲基酶-1的抑制剂 | |
| AU2014235280B2 (en) | Histone demethylase inhibitors | |
| AU2013363957B2 (en) | Histone demethylase inhibitors | |
| CN106604997B (zh) | 赖氨酸特异性脱甲基酶-1的抑制剂 | |
| CA2894399A1 (en) | Histone demethylase inhibitors | |
| EP3194387B1 (en) | Histone demethylase inhibitors | |
| EP3445752A1 (en) | Histone demethylase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: CELGENE QUANTICEL RESEARCH, INC. Free format text: FORMER OWNER(S): QUANTICEL PHARMACEUTICALS, INC. |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |